Similar articles

• Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.

  Barton P, Kalil AC, Nadel S, Goldstein B, Okhuysen-Cawley R, Brilli RJ, Takano JS, Martin LD, Quint P, Yeh TS, Dalton HJ, Gessouron MR, Brown KE, Betts H, Levin M, Macias WL, Small DS, Wyss VL, Bates BM, Utterback BG, Giroir BP. Barton P, et al. Pediatrics. 2004 Jan;113(1 Pt 1):7-17. doi: 10.1542/peds.113.1.7. Pediatrics. 2004. PMID: 14702440 Clinical Trial.
• Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.

  [No authors listed] [No authors listed] Prescrire Int. 2007 Feb;16(87):7-9. Prescrire Int. 2007. PMID: 17323514
• Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.

  De Backer D. De Backer D. Drug Saf. 2007;30(11):995-1010. doi: 10.2165/00002018-200730110-00002. Drug Saf. 2007. PMID: 17973539 Review.
• Biomarker response to drotrecogin alfa (activated) in children with severe sepsis: results from the RESOLVE clinical trial*.

  Dalton HJ, Carcillo JA, Woodward DB, Short MA, Williams MD. Dalton HJ, et al. Pediatr Crit Care Med. 2012 Nov;13(6):639-45. doi: 10.1097/PCC.0b013e318250ad48. Pediatr Crit Care Med. 2012. PMID: 22791090 Clinical Trial.
• Recombinant human activated protein C, drotrecogin alfa (activated): a novel therapy for severe sepsis.

  Kanji S, Devlin JW, Piekos KA, Racine E. Kanji S, et al. Pharmacotherapy. 2001 Nov;21(11):1389-402. doi: 10.1592/phco.21.17.1389.34417. Pharmacotherapy. 2001. PMID: 11714212 Review.